standard neoadjuvant chemoradiotherapy-Yonsei University-rectal cancer

Standard neoadjuvant chemoradiotherapy-Yonsei University-rectal cancer refers to the control treatment arm in a Phase 3 clinical trial (NCT01442428) conducted by Yonsei University for patients with locally advanced rectal cancer. This multimodal regimen consists of preoperative (neoadjuvant) concurrent chemoradiotherapy (CCRT) followed by total mesorectal excision (TME) surgery and subsequent adjuvant chemotherapy. The CCRT phase involves radiation therapy (45-50.4 Gy) combined with fluoropyrimidines, such as intravenous 5-fluorouracil (5-FU) and leucovorin or oral capecitabine. Postoperatively, patients receive adjuvant chemotherapy, which may include FOLFOX (oxaliplatin, leucovorin, and 5-FU), capecitabine, or 5-FU/leucovorin. The trial was designed to evaluate whether omitting the neoadjuvant chemoradiotherapy phase in favor of upfront surgery followed by adjuvant FOLFOX would provide non-inferior efficacy in patients with clear circumferential resection margins.

Other names

Arm A : standard neoadjuvant chemoradiotherapy groupStandard neoadjuvant chemoradiotherapy